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Abstract
Regular and prolonged exercise is associated with increased left ventricular wall thickness that can overlap with
hypertrophic cardiomyopathy (HCM). Differentiating physiological from pathological hypertrophy has important
implications, since HCM is the commonest cause of exercise-related sudden cardiac death in young individuals.
Most deaths have been reported in intermittent ‘start-stop’ sports such as football (soccer) and basketball. The
theory is that individuals with HCM are unable to augment stroke volume sufficiently to meet the demands of
endurance sports and are accordingly ‘selected-out’ of participation in such events. We report the case of an ultra-
endurance athlete with 25 years of > 50 km competitive running experience, with genetically confirmed HCM;
thereby demonstrating that these can be two compatible entities.
Keywords: Ultra-endurance exercise, hypertrophic cardiomyopathy, athlete?’?s heart, sudden cardiac death, pre-par-
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Background
Regular physical exercise is associated with physiological
increases in cardiac dimensions which may be reflected
on the electrocardiogram (ECG). Differentiating a phy-
siological or pathological remodelling mechanism is
important, as significant cardiac enlargement may be an
expression of underlying cardiac disease, placing the
athlete at a greater risk of sudden cardiac death (SCD)
[1]. Approximately 80% of non-traumatic sudden deaths
in young athletes (< 35 years) are caused by inherited or
congenital structural and functional cardiovascular
abnormalities, which provide a substrate for arrhythmias
predisposing to SCD [2]. Hypertrophic cardiomyopathy
(HCM), defined by the presence of increased ventricular
wall thickness or mass in the absence of loading condi-
tions (hypertension, valve disease, etc) sufficient to
cause the observed abnormality [3], is the leading cause
of SCD in the young and accounts for one third of all
sudden cardiac deaths in young competitive athletes
[4,5]. However, existing data also demonstrates that a
small proportion of athletes (< 2%) exhibit increased left
ventricular wall thickness (LVWT) ranging between 13-
16 mm [6-8], which overlaps with morphologically mild
HCM.
Deaths from HCM are predominantly confined to inter-
mittent ‘start-stop’ sports such as American football, bas-
ketball and soccer, with few cases reported in endurance
sports. The postulated theory is that individuals with
HCM are unable to augment cardiac output sufficiently to
participate in intensive and prolonged endurance sports
due to a combination of pronounced LVH, a non-compli-
ant LV, exercise-induced LV outflow obstruction and
microvascular ischemia. However, we report an ultra-
endurance athlete with confirmed HCM capable of per-
forming high-levels of aerobic ultra-endurance activity.
Case Presentation
A 44 year-old Caucasian male was evaluated in our cen-
tre for investigation of a cardiac murmur identified by
his primary care physician. The individual was asympto-
matic with no past medical history, medication history
or family history. He was an ultra-marathon runner with
over 25 years of competitive running history; currently
participating in 3 ultra-marathon (> 50 km) events per
year often involving challenging mountainous and fro-
zen terrain. Resting blood pressure of 95/60 mmHg and
physical examination was unremarkable apart from the
presence of a soft ejection systolic murmur.
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axis deviation, voltage criteria for bi-atrial enlargement,
LVH and significant repolarisation anomalies including
ST-segment depression in leads II, III and AVF, and
deep T-wave inversions in leads V5 and V6 (Figure 1).
Echocardiography demonstrated asymmetric septal
hypertrophy of the basal and mid-septum with a maxi-
mal LVWT of 14 mm and an end-diastolic LV diameter
of 44 mm (Figure 2a, 3a and 2b, 3b). There was no evi-
dence of systolic anterior motion of the mitral valve
leaflet or LV outflow tract obstruction. Systolic and dia-
stolic function were clinically normal; the left atrial dia-
meter measured 37 mm, the E/A ratio was > 1 (Figure
4) and tissue Doppler revealed an E’ of 16 cm/s at the
l a t e r a lL Vw a l la n d1 1c m / si nt h es e p t a lL Vw a l l( F i g -
ure 5).
Subsequent investigations included an exercise stress
test with the athlete completing 21 minutes of the Bruce
protocol (19.1 METS) corresponding to an oxygen con-
sumption of 67 ml/kg
-1/min
-1. Heart rate (91% predicted
maximum) and BP response (systolic BP rising from 98
mmHg to 168 mmHg at peak exertion) to exercise was
normal and there was no evidence of cardiac dysrhyth-
mias on exercise or on the 24-hour Holter monitor.
The abnormal resting ECG, asymmetric septal hyper-
trophy and non-dilated LV cavity raised suspicion of
HCM. However, the normal indices of diastolic function
and supra-normal functional capacity favoured ‘athlete’s
heart’. Consequently, CMR was performed using stan-
dardised imaging protocols [9]. Analysis of the short
axis images in diastole demonstrated asymmetrical
hypertrophy predominantly affecting the basal and mid
anteroseptal and inferoseptal walls (maximum wall
thickness, 17 mm). The lateral wall at the same level
measured 8.5 mm (Figure 2b, 3b). Imaging for late gado-
linium enhancement (LGE) was performed approxi-
mately 10 minutes after contrast administration using
an inversion-recovery gradient echo sequence. This
demonstrated regions of focal intramyocardial fibrosis in
the anterior and inferior basal LV-RV insertion points
(Figure 6). The degree of focal fibrosis was felt to be dis-
proportionate and not physiological. Insertion point
fibrosis has been described in cases of hypertensive
LVH, aortic stenosis and congenital heart disease [10].
In this case however, there was no history of any of the
a b o v ec o n d i t i o n sa n dh e n c eL G Ew a sc o n s i d e r e dt o
represent cardiomyopathy.
Accordingly, first-degree relatives were invited to our
centre for cardiovascular screening, which demonstrated
an abnormal ECG and echocardiogram consistent with
HCM in the mother and sister of the index case.
Genetic testing for known mutations encoding sarco-
meric contractile proteins proved positive for a mutation
in the MYBPC3 gene encoding myosin binding protein
Figure 1 12-lead ECG of a 44 year old ultra-marathon runner demonstrating first degree heart block, right axis deviation, bi-atrial
enlargement, left ventricular hypertrophy with associated ST-segment depression in leads II, III, AVF and deep T-wave inversions in
leads V5 and V6.
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22) in all three individuals.
Discussion
Previous cases of endurance athletes with HCM have
been reported [11], however, this is the first case of a
genetically proven diagnosis in an individual able to per-
form such high levels of ultra-endurance exercise for
over 25 continuous years. This case demonstrates the
challenges faced when evaluating athletes with an abnor-
mal ECG or LV hypertrophy on echocardiography and
highlights the importance of systematic evaluation that
includes LGE-CMR to determine whether such changes
represent physiological adaptation or pathological
phenomena.
The ECG presented here has numerous features com-
patible with cardiac adaptation to exercise, including
voltage criteria for LVH, ST-segment depression, a
prolonged PR interval and inverted T-waves [6,12-17].
However, T-wave inversion in V5-6 are nearly always
associated with cardiomyopathy and should always be
interpreted with suspicion for three important reasons;
1) the ECG is abnormal in 95-97% of patients with
HCM, 2) whereas voltage criteria for LVH are present
in around 75% of patients with HCM, isolated Sokolow-
Lyon voltage criterion for LVH commonly observed
within athletes (without associated ST and T wave
changes) occurs in only 2% of HCM patients, and 3)
repolarisation changes consisting of ST segment shift
and T wave inversion are present in over 90% of cases.
Whilst echocardiography demonstrated a LVWT is 14
mm at the septum, it is well established that a minority
of Caucasian athletes (< 2%) also demonstrate physiolo-
gical LVH between 13-16 mm [7,8,18]. However, physio-
logical LVH is typically associated with LV cavity
dilatation of 55-65 mm. Hence, the LV cavity size of 44
mm in this case is unexpectedly reduced and typical of
the disparity seen in individuals with HCM. Given the
diagnostic uncertainty in this athlete, this case study
also highlights the important role of including CMR in
the workup of individuals presenting “grey zone” LVH
(12-15 mm). There was a major discrepancy between
maximal LV wall thickness derived by echocardiography
(14 mm) and that of CMR (17 mm). Indeed, a wall
thickness of 17 mm is not routinely observed within
athletes regardless of body surface area [7,8] and points
ominously towards pathology. CMR provides a compre-
hensive assessment of both ischemic and non-ischemic
cardiomyopathies providing detailed precise information
on cardiac anatomy, function, tissue characterisation,
epicardial and microvascular perfusion, valvular flows,
and coronary and peripheral angiography. Measure-
ments of maximal wall thickness are highly accurate, as
is the pattern definition of LV wall thickening (focal vs.
mild concentric) and unlike echocardiography, no geo-
metrical assumptions need to be made about the ventri-
cle [19,20]. Indeed, in some regions of the LV chamber,
the extent of hypertrophy can be underestimated by
echocardiography compared to CMR [21,22], which is
not diagnostically helpful in “grey zone” athletes. Finally,
LGE provides a sensitive tool for the detection of myo-
cardial fibrosis, abnormalities not typically seen in phy-
siological LVH, thus highlighting pathology [23-25].
Due to the abnormal CMR and the abnormal cardio-
vascular evaluation of first-degree relatives, familial
disease was presumed and genetic testing confirmed a
diagnosis of HCM. Variable expression of the disease
is common, even amongst members of the same family
sharing the same gene defect. Mutations in more than
13 genes encoding sarcomeric contractile proteins have
been identified as a cause of HCM [26]. Importantly,
in a patient with an overt cardiomyopathy, the yield or
 
 
Figure 2 Trans-thoracic echocardiography (a) vs. CMR (b)
image demonstrating; asymmetric septal hypertrophy of 14
mm and a left ventricular cavity size of 44 mm in the
parasternal short axis at papillary muscle level (a) vs.
asymmetric septal hypertrophy of 17 mm, a left ventricular
cavity size of 44 mm and a lateral wall of 8.5 mm at the same
level (b).
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[27]. Failure to identify a recognised mutation does not
exclude the diagnosis of a cardiomyopathy for three
important reasons; 1) not all genetic regions are
assessed, 2) current technology is not able to detect
some forms of mutation (intronic cryptic splice sites,
large genomic rearrangements, etc), and 3) a similar
phenotype may possibly develop without a specific
 
 
Figure 3 Trans-thoracic echocardiography (a) vs. CMR (b) image demonstrating; asymmetric septal hypertrophy of 14 mm and a left
ventricular cavity size of 44 mm in the parasternal long axis at papillary muscle level (a) vs. asymmetric septal hypertrophy of 17
mm, a left ventricular cavity size of 44 mm and a lateral wall of 8.5 mm at the same level (b).
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account that genetic testing is expensive, not routinely
available in most cardiology departments and can take
up to 9 months to get a result. In our opinion, whilst
the genetic test confirmed HCM, it was the abnormal
electrocardiographic, imaging findings and family
screening that confirmed genetic HCM rather than an
athlete’s heart. The clinical impression was that if a
causative gene for HCM was not identified, the diagno-
sis of HCM would still have been made.
Recently, our laboratory recently examined the car-
diac structure and function of a unique cohort of 12
asymptomatic truly life-long, competitive veteran
endurance athletes (56 ± 6 yr), with 20 age-matched
veteran controls (60 ± 5 yr) and 17 younger male
endurance athletes (31 ± 5 yr) using LGE CMR [28].
Veteran athletes had a significantly larger LV and RV
end-diastolic and systolic volumes, intraventricular
septum thickness during diastole [mean ± SD; (range)
11 ± 1 mm (9-13 mm) vs. 10 ± 2 mm (10-13 mm), p <
0.05] and posterior wall thickness during diastole [10 ±
1m m( 8-1 1m m )v s .8±1m m( 7-1 0m m )p<
0.001], together with significantly reduced LV and RV
ejection fractions (p <0.05), compared with veteran
controls. We also observed the presence of myocardial
fibrosis in 6 (50%) of the veteran athletes, but no LGE
in the age-matched veteran controls or young athletes.
Importantly, the prevalence of LGE in veteran athletes
was significantly associated with the number of years
spent training (p < 0.001), number of competitive
marathons (p < 0.001) and ultra-endurance (> 50
miles) marathons (p < 0.007) completed, suggesting a
link between life-long endurance exercise and
‘acquired’ myocardial fibrosis that requires further
investigation. However, the extent of LVH and fibrosis
observed with these life-long veteran athletes was not
as extensive as the athlete presented here, thus point-
ing towards a pathological mechanism.
Pre-participation screening data from Italy, incorpor-
ating the 12-lead ECG, suggests that the incidence of
sudden death from HCM may be reduced through ear-
lier identification and subsequent disqualification of
 
Figure 4 Normal indices of diastolic function; mitral inflow E:A ratio of > 1.
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Page 5 of 9affected athletes from competitive sport [29]. Guide-
lines from both the ACC 36th Bethesda Conference
and ESC recommend that athletes with unequivocal or
‘probable’ HCM abstain from competitive sport and
vigorous training with the exception of low-intensity
activities [30-32]. The pathophysiology of death in an
athlete with HCM during sport is multi-factorial;
HCM has distinctive histology with affected areas of
 
 
Figure 5 Tissue Doppler analysis of longitudinal function; with an E’ of 16 cm/s in the lateral LV wall (a) and 11 cm/s in the septal LV
wall (b).
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fibrosis with gross disorganisation of the muscle bun-
dles, resulting in a characteristic whorled pattern. In
patients with HCM, the presence of fibrosis is an
important marker of risk and patients with a greater
number of risk factors for SCD typically have more
fibrosis (as found in post-mortem data) [33], that is an
independent risk for major adverse cardiac events [34].
The presence of fibrosis contributes to the disruption
of the electrical synchrony that exists between myo-
cytes and thereby increases arrhythmic potential
[35,36]. Although a risk stratification algorithm for
HCM is in existence, extrapolation of such data to an
athletic milieu with associated high circulating cate-
cholamines, acid-base shifts and electrolyte imbalances
is unrealistic. Based on these considerations the exer-
cise guidelines for this heterogeneous disorder are
homogenous and conservative [37], and include ath-
letes who may genuinely be at low risk of fatal cardiac
events, as in this particular case.
Sporting disqualification from all high-intensity ultra-
endurance activity was discussed with the athlete
together with ICD insertion. Personal and family genetic
counselling together with clinical symptom education
was given to the athlete regarding the risks of ultra-
endurance exercise and the potential for SCD. The ath-
lete and family members agreed for genetic testing, but
the athlete refused an ICD. Accordingly, the athlete is
required to undergo a comprehensive yearly cardiovas-
cular examination. However, the athlete continues to
compete in ultra-endurance running events despite
knowing the risks posed by continued high intensity
competition; and with 2 years of follow-up data he
remains asymptomatic without any significant cardiac
changes.
Conclusion
This case study reports an asymptomatic male athlete
with 25 years of ultra-endurance competition, with
genetically confirmed HCM phenotypically manifesting
with LVH, a small LV cavity together with repolarisation
abnormalities suggestive of HCM. Despite documented
asymmetric hypertrophy and focal myocardial fibrosis in
the basal anteroseptal and inferoseptal walls, it is sus-
pected that the athlete is able to run ultra-marathons
due to a compliant LV with normal diastolic and systo-
lic parameters, which is able to augment stroke volume.
I nc o n c l u s i o n ,r a r ea st h e ym i g h tb e ,am i n o r i t yo f
HCM patients are capable of life-long careers in ultra-
endurance exercise. This case also highlights the impor-
tance of systematic evaluation of all athletes with elec-
trocardiographic features suggestive of a
cardiomyopathy or ion channelopathy, with LGE CMR
(Figure 7), maximal cardiopulmonary stress testing, first-
degree family screening and where appropriate, genetic
testing, to determine whether such changes represent
physiological adaptation or pathological phenomena.
Consent
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Figure 6 Late gadolinium enhancement (A-C) at basal (A), mid (B), and apical(C) ventricular levels, demonstrating focal myocardial
fibrosis (red arrows) predominantly at basal level in the basal anteroseptal and inferoseptal walls.
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